Conditions

Long-term users of the acid reflux drugs known as Proton Pump Inhibitors (PPIs) have a 24% higher risk of developing type 2 diabetes than non-PPI users. 

This article is part of a live interview with Dr. Engel, Associate Vice President, Cardiometabolic and Women's Health, Merck Research Laboratories.

Can a virtual diabetes clinic (VDC) improve diabetes care? 

Since DPP-4 plays a role in infection for some coronaviruses, there is increased interest in whether patients using DPP-4 inhibitors are at greater pneumonia risk.

CGM use in young children with type 1 diabetes has its benefits and challenges, according to their parents.

Female, type 1 diabetes for 42 years, 58 years of age, lives with husband and dog. The patient has hypoglycemic unawareness. We regularly readjust her treatment plan and have recommended CGM for this patient on numerous occasions. Still, she refuses, stating her dog wakes her up if and when she has hypoglycemia. She called to let us know her dog passed away....

Optimize Clinical Diabetes Management with AI Technology

A new clinical software using artificial intelligence is being used for those with type 2 diabetes in Kentucky. It shows promising results in improving the Quality of Life for its residents and lowering treatment costs.

In part 3: user testimonials about the experience and exciting findings using the software. A more in-depth examination of the benefits of applying decision-support software in clinical practice.   

Collaborative Analysis Concludes that the AI Tool Improves Outcomes for Type 2 Diabetes Patients 

A new clinical software using artificial intelligence is being used for those with Type 2 diabetes in Kentucky. It shows promising results in improving the Quality of Life for its residents and lowering treatment costs. This feature is a 3-part series. 

The project was designed to address through clinical intervention the issues experienced by patients with diabetes, such as high A1c levels. Through team-based care, clinical software support, and patient engagement, the intervention was projected to help control HbA1c and potentially lower treatment costs.  

A new clinical software using artificial intelligence is being used for those with type 2 diabetes in Kentucky. It shows promising results in improving the Quality of Life for its residents and lowering treatment costs. This feature will be a 3-part series. 

In Part 1:  Adherence-related issues are hemorrhaging the costs of diabetes-related treatment in America. To offset this tragedy, GlucosePATH is utilized by a team of healthcare professionals dedicated to improving the quality of life while decreasing avoidable costs.  

Is a very low carbohydrate diet (VLCD) superior to an essential carbohydrate/low-fat diet (LFD) for improving body mass and insulin sensitivity?